Welcome to Leukemia - celebrating 30yrs of publication, 1987-2017


Leukemia covers all aspects of the research and treatment of leukemia and allied diseases. Studies of normal hemopoiesis are covered because of their comparative relevance. Topics of interest are studies on oncogenes, growth factors, stem cells, leukemia genomics, cell cycle, signal transduction, molecular targets for therapy and more.


Impact Factor: 12.104*
#1 journal in Hematology


Submit to Leukemia.

Volume 31, No 5
May 2017

ISSN: 0887-6924
EISSN: 1476-5551

2015 Impact Factor 12.104*
1/70 Hematology
8/213 Oncology

Editors-in-Chief:
Robert Peter Gale, USA
Andreas Hochhaus, Germany

*2015 Journal Citation Reports® Science Edition (Thomson Reuters, 2016)

Not to be missed

Don't miss these recently trending articles

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo
CAR-T cells represent a new and promising approach to cancer therapy, however, heterogeneity of cell products used in different clinical trials makes it difficult to interpret the basis for therapeutic success or failure. This study shows that CAR-T-cell products generated from defined T-cell subsets can provide uniform potency compared with products derived from unselected T cells that vary in phenotypic composition. These findings have important implications for the formulation of T-cell products for adoptive therapies.

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
To enable a comprehensive evaluation of the long-term benefits and risks of nilotinib and imatinib for the treatment of patients with newly diagnosed CML-CP, this study provides updated results from ENESTnd based on a minimum follow-up of five calendar years, representing the full follow-up duration designated in the original study protocol.

Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms
A quarter of patients with essential thrombocythemia (ET) or primary myelofibrosis carry a driver mutation of CALR, the calreticulin gene. This study shows differential clinical effects of mutation subtypes - Type 2-like CALR mutations are mainly associated with an ET phenotype, low risk of thrombosis and indolent clinical course, while type 1-like mutations are mainly associated with a myelofibrosis phenotype and a high risk of progression from ET to myelofibrosis.

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
Most reports on CML treatment with tyrosine kinase inhibitors (TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast, adverse events are often reported as infrequent, minor, tolerable and manageable, but they are increasingly important as therapy is potentially lifelong and multiple TKIs are available. For this reason, the European LeukemiaNet panel for CML management recommendations presents this critical summary of adverse events emerging during CML treatment, to assist their understanding, management and prevention.

News

celebration

Celebrating 30 years of publication - 1987-2017

Watch our video highlighting some of Leukemia's key achievements during 30 years of publication

Post a video summary of your research

Leukemia is pleased to announce that authors can now upload video presentations to accompany their article when published. Presentations should provide a short, succinct summary of the research and be uploaded as Supplementary Material. Whilst enhancing reader experience, video summaries also provide an excellent tool for promotion to help increase visibility and reach. Please refer to the journal's Instructions for Authors for technical specifications.

Open Access Publication
Authors of research articles can opt to pay an article processing charge (APC) for their accepted articles to be open access online immediately upon publication. Open access articles are published under Creative Commons licenses, which allow authors to retain copyright to their work while making it open to readers.
Visit our Open Research Site for detailed information about publishing open access.

Extra navigation

24 May 2017

natureevents

ADVERTISEMENT